Roivant reported a net loss of $290.6 million for the quarter ended June 30, 2026, up from $273.9 million a year earlier, on revenue of $1.4 million versus $2.2 million. Net loss per share narrowed to $0.26 from $0.33, and the net loss attributable to Roivant Sciences Ltd. was $189.8 million versus $223.4 million, while R&D and G&A expenses both rose.
Net loss per common share was $0.26 versus $0.33 a year earlier; non-GAAP net loss was $243.7 million versus $170.1 million.
R&D expenses rose $49.1 million to $202.0 million; G&A expenses rose $31.5 million to $165.5 million.
Roivant repurchased 7.3 million common shares for about $208.7 million in the quarter.
Cash, cash equivalents, restricted cash and marketable securities were $3.9 billion at June 30, 2026, excluding the $950 million Moderna payment received in July 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Roivant Sciences's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$8.26M
-71.6%
$-0.54
—
-3629.2%
FY2025
$29.05M
-11.2%
$-0.24
-104.6%
-592.0%
FY2024
$32.71M
+3.8%
$5.23
—
13294.2%
FY2023
$31.53M
-43.0%
$-1.42
—
-3200.2%
FY2022
$55.29M
+132.3%
$-1.26
—
-1528.9%
Frequently asked questions
When is Roivant Sciences's next earnings date?
Roivant Sciences (ROIV) is scheduled to report on Monday, November 09, 2026 before the market opens. Analysts expect EPS of $-0.52.
What did Roivant Sciences earn last quarter?
For the quarter ended Jun 2026, Roivant Sciences reported diluted EPS of $-0.26 on revenue of $1.44M (-33.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.